Exhausting the type I error level in event-driven group-sequential designs with a closed testing procedure for progression-free and overall survival

Moritz Fabian Danzer, Kaspar Rufibach, Jan Beyersmann +1

In oncological clinical trials, overall survival (OS) is the gold-standard endpoint, but long follow-up and treatment switching can delay or dilute detectable effects. Progression-…